Siewert Type III Adenocarcinoma of Esophagogastric Junction
5
1
1
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
3 treatments under study, led by Elective Surgery For Gastric Cancer
Research Leaders
5 sponsors active, led by P. Herzen Moscow Oncology Research Institute
Related Conditions
Often studied with 11 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 5 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (5)
Immediate and Functional Results of Different Types of Reconstructions After Proximal Gastrectomy For Gastric and Esophagogastric Junction Cancer
Morbidity and Mortality After Esophageal and Esophagogastric Junction Cancer Surgery
Postoperative Morbidity and Mortality After Gastric Cancer Surgery
Classification of Adenocarcinoma of the Esophagogastric Junction
Length of the Proximal Resection Margin for Siewert-II/Siewert-III Tumors
Research Network
Common Treatments
- Elective Surgery For Gastric Cancer2
- Proximal Gastrectomy1
- Gastrectomy1
Active Sponsors
- P. Herzen Moscow Oncology Research Institute3
- National Medical Research Radiological Centre of the Ministry of Health of Russia2
- St. James's Hospital, Ireland1
- A.Loginov Moscow Clinical Scientific Center1
- West China Hospital1
Top Investigators
P.Herzen Moscow Oncological Research Institute
P.Herzen Moscow Oncological Research Institute
P.Herzen Moscow Oncological Research Institute
P.Herzen Moscow Oncological Research Institute
West China Hospital
Related Conditions
- Siewert Type Ii Adenocarcinoma Of Esophagogastric Junction3
- Siewert Type I Adenocarcinoma Of Esophagogastric Junction2
- Esophageal Cancer1
- Recurrence1
- Barrett Esophagus1